About this FactMed analysis covering adverse side effect reports of ALMARL patients who developed HALLUCINATION.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 15 individuals taking ALMARL reported HALLUCINATION to the FDA. A total of 227 ALMARL drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between ALMARL and HALLUCINATION. In doing so, we compare ALMARL with other drugs that cause HALLUCINATION, to help you evaluate whether or not ALMARL causes HALLUCINATION. Likewise, this page shows the most highly-reported side effects of ALMARL, so you can see if HALLUCINATION ranks among ALMARL's most well-known side effects.
Summary Statistics
Reports of ALMARL causing HALLUCINATION: 15
Reports of any side effect of ALMARL : 227
Percentage of ALMARL patients where HALLUCINATION is a reported side effect: 6.6079%

FDA reports of any drug causing HALLUCINATION : 22255
Average percentage for all medicated patients where HALLUCINATION is reported as a complication: 0.1395%

Physician opinion on ALMARL as adverse event culprit:

Overall opinion for all reports of this drug:
Most frequent diagnoses/indications for prescribing ALMARL:
HYPERTENSION ( 76 patients )
PARKINSON'S DISEASE ( 8 patients )
ESSENTIAL TREMOR ( 6 patients )
ATRIAL FIBRILLATION ( 4 patients )
SCHIZOPHRENIA ( 2 patients )
TREMOR ( 2 patients )
ANGINA PECTORIS ( 2 patients )
DRUG USE FOR UNKNOWN INDICATION ( 2 patients )
PALPITATIONS ( 2 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 2 patients )
TACHYCARDIA ( 2 patients )
HYPERTROPHY ( 1 patients )
( 0 patients )
Drugs with high FDA adverse event association with HALLUCINATION:

SEROQUEL (1874 patients)
CHANTIX (1465 patients)
ASPIRIN (1354 patients)
LYRICA (922 patients)
AMBIEN (735 patients)
CYMBALTA (724 patients)
XANAX (709 patients)
NEURONTIN (706 patients)
RISPERDAL (682 patients)
ZOLOFT (651 patients)
PAXIL (616 patients)
ZYPREXA (593 patients)
LASIX (578 patients)
FUROSEMIDE (568 patients)
TAMIFLU (562 patients)
OMEPRAZOLE (538 patients)
SYNTHROID (525 patients)
LIPITOR (514 patients)
FOSAMAX (510 patients)
OXYCONTIN (506 patients)
ACETAMINOPHEN (496 patients)
LEXAPRO (496 patients)
SIMVASTATIN (477 patients)
NEXIUM (476 patients)
ATIVAN (475 patients)
ALBUTEROL (466 patients)
LISINOPRIL (445 patients)
ABILIFY (438 patients)
ATENOLOL (437 patients)
REQUIP (433 patients)
LORAZEPAM (426 patients)
CLONAZEPAM (415 patients)
EXELON (413 patients)
SINGULAIR (410 patients)
WELLBUTRIN (405 patients)
SUBOXONE (399 patients)
VALTREX (398 patients)
PLAVIX (391 patients)
LEVAQUIN (391 patients)
GABAPENTIN (389 patients)
PREDNISONE (382 patients)
MORPHINE (362 patients)
KLONOPIN (361 patients)
TRAMADOL HCL (360 patients)
AVONEX (358 patients)
DIGOXIN (353 patients)
TOPROL-XL (352 patients)
DURAGESIC-100 (348 patients)
SINEMET (346 patients)
METFORMIN HCL (343 patients)
ARICEPT (343 patients)
NAMENDA (337 patients)
EFFEXOR (335 patients)
DIAZEPAM (325 patients)
COUMADIN (322 patients)
DEPAKOTE (320 patients)
PREDNISOLONE (317 patients)
ZOMETA (314 patients)
HYDROCHLOROTHIAZIDE (308 patients)
NORVASC (305 patients)
GEODON (295 patients)
VIOXX (294 patients)
LAMICTAL (293 patients)
FENTANYL (292 patients)
PROZAC (292 patients)
RELENZA (286 patients)
HEPARIN SODIUM INJECTION (282 patients)
ZOCOR (282 patients)
WARFARIN SODIUM (281 patients)
PRILOSEC (281 patients)
MIRTAZAPINE (277 patients)
CITALOPRAM HYDROBROMIDE (274 patients)
HALDOL (273 patients)
VICODIN (273 patients)
PROTONIX (270 patients)
LEVOTHYROXINE SODIUM (269 patients)
RAMIPRIL (264 patients)
PERCOCET (261 patients)
POTASSIUM CHLORIDE (261 patients)
IBUPROFEN (261 patients)
ALPRAZOLAM (259 patients)
AMITRIPTYLINE HCL (258 patients)
OXYCODONE HCL (258 patients)
AVELOX (255 patients)
MIRAPEX (255 patients)
LORTAB (254 patients)
CELEBREX (251 patients)
FOLIC ACID (249 patients)
PAROXETINE HCL (247 patients)
ALLOPURINOL (244 patients)
BACLOFEN (243 patients)
NITROGLYCERIN (241 patients)
STALEVO 100 (240 patients)
CLOZARIL (239 patients)
TRAZODONE HCL (235 patients)
CELEXA (235 patients)
VALIUM (233 patients)
ALL OTHER THERAPEUTIC PRODUCTS (231 patients)
RISPERIDONE (228 patients)
EFFEXOR XR (228 patients)
CONCERTA (228 patients)
SPIRIVA (228 patients)
LANTUS (227 patients)
TEGRETOL (220 patients)
PREVACID (218 patients)
AREDIA (217 patients)
MORPHINE SULFATE (217 patients)
TOPAMAX (216 patients)
BENADRYL (213 patients)
PREMARIN (213 patients)
ADVAIR DISKUS 100/50 (213 patients)
METOPROLOL TARTRATE (212 patients)
KEPPRA (207 patients)
FENTANYL-100 (206 patients)
CLOZAPINE (204 patients)
MULTI-VITAMIN (202 patients)
SEROQUEL XR (202 patients)
TYSABRI (201 patients)
CRESTOR (199 patients)
INSULIN (195 patients)
LUNESTA (187 patients)
AMLODIPINE (187 patients)
VFEND (185 patients)
MULTI-VITAMINS (183 patients)
COMTAN (182 patients)
VITAMIN D (180 patients)
DEXAMETHASONE (179 patients)
METOPROLOL (177 patients)
FLEXERIL (174 patients)
TYLENOL (CAPLET) (173 patients)
ZYRTEC (172 patients)
HALOPERIDOL (169 patients)
ACYCLOVIR (168 patients)
ALLEGRA (166 patients)
DIOVAN (162 patients)
VERAPAMIL (161 patients)
LITHIUM CARBONATE (159 patients)
LANSOPRAZOLE (158 patients)
REVLIMID (156 patients)
MADOPAR (153 patients)
LOPRESSOR (151 patients)
FLOMAX (151 patients)
REMERON (149 patients)
RESTORIL (149 patients)
REMICADE (148 patients)
MS CONTIN (147 patients)
COZAAR (147 patients)
NICOTINE (147 patients)
VITAMIN E (146 patients)
PREDNISONE TAB (145 patients)
ZOLPIDEM (145 patients)
CALCIUM (145 patients)
TYLENOL (144 patients)
COLACE (142 patients)
DECADRON (141 patients)
METHADONE HCL (140 patients)
CLONIDINE (140 patients)
ZITHROMAX (139 patients)
RIBAVIRIN (138 patients)
STRATTERA (138 patients)
CLARITIN (133 patients)
FLUOXETINE (133 patients)
METHOTREXATE (132 patients)
ENALAPRIL MALEATE (132 patients)
CIPROFLOXACIN (132 patients)
PRAMIPEXOLE DIHYDROCHLORIDE (132 patients)
RISPERDAL CONSTA (130 patients)
CLARITHROMYCIN (129 patients)
ZANTAC (129 patients)
AMANTADINE HCL (129 patients)
DILAUDID (129 patients)
ZOVIRAX (128 patients)
RANITIDINE (128 patients)
METOPROLOL SUCCINATE (128 patients)
REBIF (128 patients)
COGENTIN (126 patients)
TEMAZEPAM (125 patients)
COMPAZINE (125 patients)
LIORESAL (124 patients)
ASCORBIC ACID (124 patients)
GAMMAGARD LIQUID (124 patients)
CALONAL (124 patients)
OXYCODONE (123 patients)
TRILEPTAL (122 patients)
AMOXICILLIN (120 patients)
LAMOTRIGINE (120 patients)
VANCOMYCIN (120 patients)
VITAMIN B-12 (119 patients)
RITALIN (119 patients)
ZOFRAN (119 patients)
MOTRIN (119 patients)
LOVENOX (119 patients)
OLANZAPINE (118 patients)
ZOLPIDEM TARTRATE (117 patients)
FORMOTEROL FUMARATE (117 patients)
RIVOTRIL (117 patients)
ALCOHOL (115 patients)
CARBIDOPA AND LEVODOPA (113 patients)
GLUCOPHAGE (112 patients)
ZETIA (111 patients)
BETASERON (111 patients)
COREG (110 patients)
VYVANSE (110 patients)
PARACETAMOL (110 patients)
ULTRAM (110 patients)
HYDROCODONE (109 patients)
FORTEO (109 patients)
PROVIGIL (108 patients)
COMBIVENT (108 patients)
PRAVASTATIN (107 patients)
Most common side effects for patients taking ALMARL:
DEPRESSED LEVEL OF CONSCIOUSNESS (20 patients)
HALLUCINATION (15 patients)
FALL (13 patients)
HYPOGLYCAEMIA (13 patients)
PYREXIA (12 patients)
TREMOR (12 patients)
DIARRHOEA (11 patients)
HEPATIC FUNCTION ABNORMAL (11 patients)
PNEUMONIA (10 patients)
DYSARTHRIA (10 patients)
BLOOD CREATINE PHOSPHOKINASE INCREASED (9 patients)
RENAL FAILURE ACUTE (9 patients)
LIVER DISORDER (9 patients)
CEREBRAL INFARCTION (8 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (8 patients)
DRUG INEFFECTIVE (8 patients)
RENAL IMPAIRMENT (8 patients)
HYPONATRAEMIA (8 patients)
INTERSTITIAL LUNG DISEASE (8 patients)
JAUNDICE (8 patients)
OEDEMA PERIPHERAL (8 patients)
CONDITION AGGRAVATED (7 patients)
DELIRIUM (7 patients)
DYSPHAGIA (7 patients)
DYSPNOEA (7 patients)
HYPOAESTHESIA (7 patients)
RHABDOMYOLYSIS (7 patients)
VOMITING (6 patients)
DELUSION (6 patients)
RESPIRATORY FAILURE (6 patients)
DYSKINESIA (6 patients)
SOMNOLENCE (6 patients)
HEPATIC NEOPLASM MALIGNANT (6 patients)
HYPERGLYCAEMIA (6 patients)
HYPOKALAEMIA (6 patients)
MOVEMENT DISORDER (6 patients)
MUSCULAR WEAKNESS (6 patients)
WHITE BLOOD CELL COUNT INCREASED (5 patients)
BLADDER CANCER (5 patients)
BLOOD ANTIDIURETIC HORMONE INCREASED (5 patients)
RESTLESSNESS (5 patients)
BLOOD OSMOLARITY DECREASED (5 patients)
PLEURAL EFFUSION (5 patients)
C-REACTIVE PROTEIN INCREASED (5 patients)
CONVULSION (5 patients)
RENAL DISORDER (5 patients)
VITH NERVE PARALYSIS (5 patients)
INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION (5 patients)
INTESTINAL OBSTRUCTION (5 patients)
SEPSIS (5 patients)
ROAD TRAFFIC ACCIDENT (5 patients)
MUSCULOSKELETAL PAIN (5 patients)
NAUSEA (5 patients)
ANOREXIA (4 patients)
ATELECTASIS (4 patients)
ATRIAL FIBRILLATION (4 patients)
ATRIOVENTRICULAR BLOCK (4 patients)
BLOOD CREATININE INCREASED (4 patients)
BRADYCARDIA (4 patients)
CARDIAC FAILURE (4 patients)
CONSTIPATION (4 patients)
DECREASED APPETITE (4 patients)
DEHYDRATION (4 patients)
DIZZINESS (4 patients)
PLATELET COUNT DECREASED (4 patients)
PAIN (4 patients)
HYPERTENSION (4 patients)
HYPOTHYROIDISM (4 patients)
ILEUS (4 patients)
METABOLIC ACIDOSIS (4 patients)
SMALL INTESTINE CARCINOMA (4 patients)
URINE OSMOLARITY INCREASED (4 patients)
ABASIA (3 patients)
AGGRESSION (3 patients)
PRURITUS (3 patients)
ANAEMIA (3 patients)
PULMONARY ALVEOLAR HAEMORRHAGE (3 patients)
WHITE BLOOD CELL COUNT DECREASED (3 patients)
ASTHMA (3 patients)
BLOOD BILIRUBIN INCREASED (3 patients)
RENAL FAILURE (3 patients)
BLOOD PRESSURE DECREASED (3 patients)
BLOOD PRESSURE INCREASED (3 patients)
VASCULITIS (3 patients)
CAROTID ARTERY STENOSIS (3 patients)
THERAPEUTIC AGENT TOXICITY (3 patients)
CHILLS (3 patients)
CHROMATURIA (3 patients)
PETECHIAE (3 patients)
CHRONIC LYMPHOCYTIC LEUKAEMIA (3 patients)
PORIOMANIA (3 patients)
RENAL ARTERY STENOSIS (3 patients)
PANCYTOPENIA (3 patients)
DRUG ERUPTION (3 patients)
SUDDEN ONSET OF SLEEP (3 patients)
DRUG WITHDRAWAL SYNDROME (3 patients)
VERTIGO (3 patients)
EPILEPSY (3 patients)
FACE OEDEMA (3 patients)
VOLVULUS (3 patients)
GENERALISED OEDEMA (3 patients)
GINGIVAL BLEEDING (3 patients)
HAEMORRHAGE SUBCUTANEOUS (3 patients)
HALLUCINATION, VISUAL (3 patients)
PSYCHIATRIC SYMPTOM (3 patients)
HEART RATE DECREASED (3 patients)
HELICOBACTER TEST POSITIVE (3 patients)
HEPATITIS FULMINANT (3 patients)
HYPERKALAEMIA (3 patients)
HYPOTENSION (3 patients)
IDIOPATHIC THROMBOCYTOPENIC PURPURA (3 patients)
LOSS OF CONSCIOUSNESS (3 patients)
SENSORY DISTURBANCE (3 patients)
LYMPHOMA (3 patients)
MALAISE (3 patients)
MARKEDLY REDUCED DIETARY INTAKE (3 patients)
RENAL TUBULAR DISORDER (3 patients)
NEOPLASM MALIGNANT (3 patients)
SINUS ARREST (3 patients)
ABDOMINAL DISCOMFORT (2 patients)
ABDOMINAL PAIN (2 patients)
ACUTE MYELOID LEUKAEMIA (2 patients)
STOMACH MASS (2 patients)
PERSONALITY CHANGE (2 patients)
AGITATION (2 patients)
ALTERED STATE OF CONSCIOUSNESS (2 patients)
ANAPHYLACTOID REACTION (2 patients)
ANGER (2 patients)
PRODUCTIVE COUGH (2 patients)
RENAL CYST (2 patients)
APHASIA (2 patients)
ASTHENIA (2 patients)
ATRIOVENTRICULAR BLOCK COMPLETE (2 patients)
THIRST (2 patients)
PROSTATE CANCER (2 patients)
BLOOD AMYLASE INCREASED (2 patients)
BLOOD UREA INCREASED (2 patients)
BODY TEMPERATURE INCREASED (2 patients)
SPEECH DISORDER (2 patients)
TUMOUR LYSIS SYNDROME (2 patients)
CEREBRAL HAEMORRHAGE (2 patients)
CHEST X-RAY ABNORMAL (2 patients)
COLON CANCER (2 patients)
COMA HEPATIC (2 patients)
COMPLETED SUICIDE (2 patients)
CONTUSION (2 patients)
PERFORMANCE STATUS DECREASED (2 patients)
DEFAECATION URGENCY (2 patients)
DEMENTIA ALZHEIMER'S TYPE (2 patients)
RASH PRURITIC (2 patients)
DIABETIC KETOACIDOSIS (2 patients)
DRUG INTERACTION (2 patients)
DRUG LEVEL INCREASED (2 patients)
DYSPEPSIA (2 patients)
DYSSTASIA (2 patients)
ELECTROCARDIOGRAM QT PROLONGED (2 patients)
STEVENS-JOHNSON SYNDROME (2 patients)
EPULIS (2 patients)
EXTRAOCULAR MUSCLE PARESIS (2 patients)
FACIAL PARESIS (2 patients)
FEAR (2 patients)
FEBRILE NEUTROPENIA (2 patients)
FEMORAL NECK FRACTURE (2 patients)
FOOT FRACTURE (2 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (2 patients)
GANGRENE (2 patients)
GASTRIC ULCER HAEMORRHAGE (2 patients)
GINGIVAL HYPERTROPHY (2 patients)
GLOSSOPTOSIS (2 patients)
PLEURISY (2 patients)
PHRENIC NERVE PARALYSIS (2 patients)
HAEMATEMESIS (2 patients)
HAEMATURIA (2 patients)
HAEMOGLOBIN DECREASED (2 patients)
POLLAKIURIA (2 patients)
ORAL INTAKE REDUCED (2 patients)
HEPATIC CYST (2 patients)
HEPATIC ENCEPHALOPATHY (2 patients)
HEPATITIS (2 patients)
HYPERREFLEXIA (2 patients)
HYPERTONIA (2 patients)
HYPERURICAEMIA (2 patients)
RASH PAPULAR (2 patients)
INITIAL INSOMNIA (2 patients)
RETINAL OEDEMA (2 patients)
INTESTINAL FUNCTIONAL DISORDER (2 patients)
RESPIRATION ABNORMAL (2 patients)
IRRITABILITY (2 patients)
RIB FRACTURE (2 patients)
LEG AMPUTATION (2 patients)
LYMPHADENOPATHY (2 patients)
METABOLIC ALKALOSIS (2 patients)
ORAL HERPES (2 patients)
TAKAYASU'S ARTERITIS (2 patients)
MOUTH HAEMORRHAGE (2 patients)
UNRESPONSIVE TO STIMULI (2 patients)
TOXIC SKIN ERUPTION (2 patients)
NEPHROLITHIASIS (2 patients)
SUICIDE ATTEMPT (2 patients)
VENTRICULAR FIBRILLATION (2 patients)
NEUTROPHIL COUNT DECREASED (2 patients)
UPPER RESPIRATORY TRACT INFECTION (2 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (2 patients)
SHOCK HAEMORRHAGIC (2 patients)
ABDOMEN CRUSHING (1 patients)
CARDIAC FAILURE CONGESTIVE (1 patients)
EOSINOPHILIC PNEUMONIA ACUTE (1 patients)
ESSENTIAL TREMOR (1 patients)
WRONG TECHNIQUE IN DRUG USAGE PROCESS (1 patients)
FUNGAL INFECTION (1 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.


Recent FactMed Activity for ALMARL


Issue Description / Topic Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about HALLUCINATION and ALMARL, post it here. You may receive a response from a fellow patient - or a leading expert in the field.
Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking ALMARL, post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.
Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in ALMARL. This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.
We are currently accepting registration for ALMARL experts. If you are a healthcare provider experienced in prescribing ALMARL, please register here.

Your online appointment book for Lansing Rentals & Services

© 2014 FactMed, Inc
Privacy Policy
Terms of Use